Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Summary

Firefly Neuroscience and Next Health launched a precision cognitive health platform integrating Firefly’s FDA-cleared AI-powered EEG/ERP brain biomarker technology with personalized cognitive peptide protocols. The initiative follows an FDA Advisory Committee recommendation supporting broader access to neuroprotective peptides such as Epitalon and Semax. It enables objective measurement of brain function to personalize, monitor, and optimize emerging cognitive therapies in longevity and clinical settings.